Combinatory treatment with CpG-Stat3 siRNA and CTLA4 antibody in A20 lymphoma tumor-bearing mice significantly increased the percentages of IFNγ and/or granzyme B (GZMB) producing CD4+ T cells and CD8+ T cells in tumors compared to either CpG-Stat3 siRNA or CTLA4 antibody alone (Figures 2A–2C). The gene discussed is STAT3; the disease is neoplasm.